 |
|
|
| |
Hepatitis B virus reactivation in people living with
HIV switching to long acting-cabotegravir/rilpivirine therapy:
a cohort study analysis
|
| |
| |
EACS 2025 Oct 18-22 Paris
A. Foncillas1,1, L. De La Mora1, B. Torres1, A. Inciarte1, M. Martínez-Rebollar1, L. Berrocal1, E. De Lazzari1, J. Calvo1, I. Chivite1, A. Sempere1, J. Ambrosioni1, J.L. Blanco1, JM Miró1, E. Martínez1, J. Mallolas1, A. González-Cordón1, M. Laguno1, HIV-Clinic Study Group
1Hospital Clínic de Barcelona, Universitat de Barcelona, HIV/AIDS Unit, Barcelona, Spain
--------------------------------------------------------
Previously reported, USA
Hepatitis B Infection or Reactivation After Switch to 2-Drug Antiretroviral Therapy: A Case Series, Literature Review, and Management Discussion USA We present 4 cases of HBV infection or reactivation after switch to 2-drug ART without HBV activity (Table 1). These occurred over 1 year during which 332 PWH were prescribed 2-drug ART in our health system. We review recommendations for HBV prevention and treatment among PWH and propose careful patient selection and monitoring during ART switch.
CROI 2025: HBV Reactivation Post-switch to HBV-inactive ART: A Scoping Review
IDWeek 2023: Hepatitis B Reactivation in Persons with HIV with Positive Hepatitis B Core Antibody after Switching to Antiretroviral Therapy without Hepatitis B Activity
HBV Reactivation in PWH Switching to TDF/TAF Sparing Therapy
|
| |
|
|
|
|
|
